We are focusing on a few key molecular
pathways including; 1) Polycomb - mediated epigenetic gene silencing in the tumor initiation, maintenance, and invasion, 2) c - Met (receptor tyrosine
kinase)
signal transduction pathways in stemness and migration of these tumor cells, 3) Novel mitogenic
signaling pathways that are specific to GSCs, and 4) Identification of radio - and chemo - sensitizing
pathway to maximize therapeutic efficacy.
Vorinostat interferes with the
signaling transduction pathway of T - cell receptor and synergizes with phosphoinositide - 3
kinase inhibitors in cutaneous T - cell lymphoma